TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03091543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 50 mg dose
Description: 2 capsules of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 50 mg dose
Description: 2 capsules of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 50 mg dose
Description: 2 capsules of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 50 mg dose
Description: 2 capsules of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 50 mg dose
Description: 2 capsules of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg dose
Description: 1 capsule of 100 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg dose
Description: 1 capsule of 100 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg dose
Description: 1 capsule of 100 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg dose
Description: 1 capsule of 100 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg dose
Description: 1 capsule of 100 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 200 mg dose
Description: 2 capsules of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 200 mg dose
Description: 2 capsules of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 200 mg dose
Description: 2 capsules of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 200 mg dose
Description: 2 capsules of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 200 mg dose
Description: 2 capsules of 100 mg
Study: NCT04164732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04138953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial Magnetic Stimulation (TMS)
Study: NCT03646864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.
Study: NCT04712448

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-COVID test
Description: No intervention is foreseen by the protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-COVID test
Description: No intervention is foreseen by the protocol
Study: NCT02436096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet, 2.8mg
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT04785742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib
Study: NCT01918995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Intravenous (IV)
Study: NCT01540071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX 194204
Description: NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
Study: NCT01918995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV)
Study: NCT01370161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS treatment
Description: 1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.
Study: NCT04535869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG plus Daclatasvir 200mg
Description: This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
Study: NCT00686829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc maleate
Description: VCV 30 mg tablet once daily by mouth.
Study: NCT01609855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine Butyl Bromide 20mg/2 ml i.v.
Description: Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 2 ml i.v.
Description: Administration of Saline 2 ml at time of caecal intubation
Study: NCT01602367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 6 mg, Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 15 mg, Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 12 weeks
Study: NCT00858065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening Families Program (SFP)
Description: Prevention program with 7 weekly group sessions for parent and child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening Families Program (SFP)
Description: Prevention program with 7 weekly group sessions for parent and child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Matters
Description: Prevention program with 4 booklets for families to do at home with their child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Matters
Description: Prevention program with 4 booklets for families to do at home with their child.
Study: NCT04075500

Intervention type: DEVICE
Group type: OTHER
Intervention: 24-h Holter monitoring
Description: Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
Study: NCT01016665

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Tamoxifen 20mg and anastrozole 1 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Tamoxifen 20mg and anastrozole 1 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Tamoxifen 20mg and anastrozole 1 mg
Study: NCT02349295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q4W
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q2W
Description: Administered SC
Study: NCT02375620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Study: NCT01198080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133+ cells
Description: bone marrow derived CD133+ cells injection with core compression
Study: NCT04263025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Umbilical Cord Allograft
Description: CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Prostatectomy
Description: Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-Assisted Radical Prostatectomy
Description: Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
Study: NCT03392246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene
Study: NCT00956865

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voucher
Description: Vouchers given to reimburse transportation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voucher
Description: Vouchers given to reimburse transportation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voucher
Description: Vouchers given to reimburse transportation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: Telephone reminder calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: Telephone reminder calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact
Description: Contact at senior center to encourage follow up
Study: NCT03806153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphokinetic
Description: The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morphokinetic
Description: The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
Study: NCT00379613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered
Study: NCT03789266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: drain ablation
Description: drain ablation will be done in Aspiration mode or in non Aspiration mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drain ablation
Description: drain ablation will be done in Aspiration mode or in non Aspiration mode
Study: NCT02002481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transport
Description: The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
Study: NCT04461951

Intervention type: OTHER
Intervention: Lifestyles (exposure)
Description: no intervention
Study: NCT01659931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 10 mg Tablet
Study: NCT03722186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1603
Description: SHR-1603 monotherapy
Study: NCT02612948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: escalating dose to prevent delerium.
Study: NCT02141126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Standard inpatient 'usual care' physiotherapy
Study: NCT02526693

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pupillometer
Description: The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pupillometer
Description: The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
Study: NCT05564234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy then primary cytoreductive surgery
Description: Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery
Description: Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
Study: NCT01798927

Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle foot orthosis
Description: Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
Study: NCT01201590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Cocoa
Description: cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Cocoa
Description: cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
Study: NCT04562480

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT02100176

Intervention type: OTHER
Intervention: Multidisciplinary intensive rehabilitation treatment
Description: The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.

Intervention type: DRUG
Intervention: Rotigotine
Description: Rotigotine 2-8 mg/24 h

Intervention type: DRUG
Intervention: Rotigotine
Description: Rotigotine 2-8 mg/24 h
Study: NCT02280044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rifaximin intervention
Description: Rifaximin administered then Challenge with C jejuni

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo administered then Challenge with C jejuni
Study: NCT04499092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Neuropsychological treatment (CORE-ABI)
Description: Personalized neuropsychological treatment. In the CORE-ABI intervention, the stimulation of cognitive functions will be provided based on a weekly evaluation of child's cognitive profile by a qualified neuropsychologist. Each session will have a duration of 45 min. While the first 30 minutes will be devoted to the stimulation of the most impaired cognitive function(s), the remaining 15 minutes will ensure the stimulation of the other cognitive subdomains. Domains addressed by the intervention will be the following: selective attention, sustained and divided attention, inhibition and shifting, visual-perceptual abilities, visual-spatial abilities, visual-constructional abilities, short-term memory, long-term memory, working-memory, categorization/reasoning/abstraction, problem-solving/planning and socio-emotional skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Neuropsychological treatment (SET-ABI)
Description: Sequential Neuropsychological Treatment. In the SET-ABI intervention, the stimulation of cognitive functions will be provided following a sequential order, identical for each child and for each session in each setting (neuropsychological treatment, speech therapy treatment and psychoeducational treatment). Each session will have a duration of 45 min.~Specifically, the first three weeks (weeks 1-3) of treatment will target attention; in weeks 4-6, the domain of visual-spatial and visual-constructional abilities will be addressed; in weeks 7-9, memory will be the target domain; in weeks 10-12, executive functions and socio-emotional skills will be addressed.
Study: NCT00299650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisatracurium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological serum infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium besilate
Description: Cisatracurium besilate infusion (900mg/day)
Study: NCT01852539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
Study: NCT03316014

Intervention type: OTHER
Intervention: Adverse drug reaction
Description: description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
Study: NCT02901210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified delorme procedure
Study: NCT02256124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo